The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Shavlovskaya O.A.

International University of Restorative Medicine», Moscow, Russia

Recognan (citicoline) in the correction of asthenic and anxiety-depressive disorders

Authors:

Shavlovskaya O.A.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2024;124(6): 43‑47

DOI: 10.17116/jnevro202412406143

Read: 3071 times

Download PDF (RU)
Contact the author
Table of contents

RECOGNAN (CITICOLINE) IN THE CORRECTION OF ASTHENIC AND ANXIETY-DEPRESSIVE DISORDERS
RECOGNAN (CITICOLINE) IN THE CORRECTION OF ASTHENIC AND ANXIETY-DEPRESSIVE DISORDERS

To cite this article:

Shavlovskaya OA. Recognan (citicoline) in the correction of asthenic and anxiety-depressive disorders. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;124(6):43‑47. (In Russ.)
https://doi.org/10.17116/jnevro202412406143

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
The gut microbiota in bipo­lar diso­rder. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):28-33
Como­rbidity of depression and deme­ntia: epidemiological, biological and therapeutic aspe­cts. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):113-121
Online phenotypes of depression symptoms are asso­ciated with poly­genic risk scores of soma­tic diseases in a popu­lation-based cohort. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):122-131
Subjective sleep quality evaluation in patients with neuromyelitis optica spectrum diso­rders. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(12):57-61
Como­rbid anxiety diso­rders in patients with neurological pathology: current state of the problem and the role of etifoxine in treatment stra­tegy. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(12):126-136
Pathogenetic inte­rrelations of hypo­gonadism and depression in men. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(1):17-23
Nutritional care for patients with neurodegenerative diseases in the outpatient practice of a neurologist. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(1):76-83
Asso­ciation between the vita­min D level and depression in the elde­rly people in the Euro­pean North of Russia. Russian Journal of Preventive Medi­cine. 2024;(12):107-113
Atopic dermatitis and skin toxic reactions: comparative characteristics, psychosomatic aspe­cts and patient mana­gement tactics. Russian Journal of Clinical Dermatology and Vene­reology. 2024;(6):744-752
Influence of enzy­matic acti­vity of microbiota on hemo­dynamics, arte­rial stiffness and emotional state of patients with mild-to-moderate risk of cardiovascular complications. Russian Cardiology Bulletin. 2024;(4-2):128-136
Abstract:

The article reflects the results of a number of studies that demonstrate the therapeutic effectiveness of Recognan (citicoline) in anxiety-depressive and asthenic disorders against the background of somatic and neurological diseases, in the correction of post-stroke depression. Recent experimental animal studies prove the effect of citicoline on anxiety and depression. In the complex effect, Recognan potentiates the main pharmacological effect of antidepressants and anxiolytics. In some studies, a dose-dependent change in animal behavior has been observed in response to the analgesic and antidepressant effects of citicoline. The effectiveness of citicoline in combination with transcranial direct current stimulation in the treatment of depression has been shown. The analysis of these research materials allows us to recommend Recognan in the complex therapy of asthenic and anxiety-depressive disorders in response to such pathological conditions as anxiety, asthenia, depression.

Keywords:

citicoline
Recognan
asthenia
anxiety
depression

Authors:

Shavlovskaya O.A.

International University of Restorative Medicine», Moscow, Russia

Received:

10.04.2024

Accepted:

16.04.2024

Close metadata

References:

  1. Amnzade A, Zarrindast MR, Khakpai F. Additive anxiolytic-like effect of citicoline and ACPA in the non-acute restraint stress (NARS) and acute restraint stress (ARS) mice. Physiol Behav. 2024;277:114506. https://doi.org/10.1016/j.physbeh.2024.114506
  2. Secades JJ. Citicoline: pharmacological and clinical review, 2010 update. Rev Neurol. 2011;52(suppl 2):S1-62. 
  3. Abdolmaleki A, Moghimi A, Ghayour MB, Rassouli MB. Evaluation of neuroprotective, anticonvulsant, sedative and anxiolytic activity of citicoline in rats. Eur J Pharmacol. 2016;789:275-279.  https://doi.org/10.1016/j.ejphar.2016.07.048
  4. Secades JJ, Gareri P. Citicoline: pharmacological and clinical review, 2022 update. Rev Neurol. 2022;75(supll 5):S1-89.  https://doi.org/10.33588/rn.75S05.2022311
  5. Secades JJ, Trimmel H, Salazar B, González JA. Citicoline for the Management of Patients with Traumatic Brain Injury in the Acute Phase: A Systematic Review and Meta-Analysis. Life. 2023;13:369.  https://doi.org/10.3390/life13020369
  6. Castagna A, Manzo C, Fabbo A, et al. The CITIMERIVA Study: CITIcoline plus MEmantina plus RIVAstigmine in older patients affected with Alzheimer’s disease. Clin Drug Invest. 2021;41(2):177-182.  https://doi.org/10.1007/s40261-020-00996-2
  7. Akhondzadeh S, Gerbarg PL, Brown RP. Nutrients for prevention and treatment of mental health disorders. Psych Clin North Am. 2013;36(1):25-36.  https://doi.org/10.1016/j.psc.2012.12.003
  8. Gareri P, Gallelli L, Cotroneo AM, et al. The art of safe and judicious deprescribing in an elderly patient: a case report. Geriatrics (Basel). 2020;5(3):57.  https://doi.org/10.3390/geriatrics5030057
  9. Nemkova SA, Semenov DV, Petrova EA, et al. Current treatment options for autonomic, cognitive and emotional disorders in patients with asthenic syndrome treated with recognan (citicoline). S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(7):27-34. (In Russ.). https://doi.org/10.17116/jnevro201911907127
  10. Nemkova SA, Semenov DV, Zavadenko NN, Vozvyshaeva MYu. Features of positive personality phenomena in patients with mild cognitive impairment and asthenic syndrome treated with recognan (citicoline). S.S. Korsakov Journal of Neurology and Psychiatry. 2020;120(1):44-50. (In Russ.). https://doi.org/10.17116/jnevro202012001144
  11. Nemkova SA, Semenov DV, Zavadenko NN, Vozvyshaeva MYu. The influence of the drug recognan (citicoline) on neurodynamic characteristics of mental activity in patients with mild cognitive impairment. S.S. Korsakov Journal of Neurology and Psychiatry. 2021;121(1):43-46. (In Russ.). https://doi.org/10.17116/jnevro202112101143
  12. Nemkova SA, Semenov DV, Petrova EA, et al. The effect of the use of the drug Recognan (Citicoline) on the state of higher mental functions in patients with mild cognitive impairment. S.S. Korsakov Journal of Neurology and Psychiatry. 2021;121(9):51-57. (In Russ.). https://doi.org/10.17116/jnevro202112109151
  13. Chutko LS, Surushkina SY, Yakovenko EA, et al. Impairments of cognitive control in patients with somatoform disorders and their treatment. S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(4):32-37. (In Russ.). https://doi.org/10.17116/jnevro201911904132
  14. Shavlovskaya OA, Bokova IA. Asthenic disorders correction with Recognan. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;124(3):57-62. (In Russ.). https://doi.org/10.17116/jnevro202412403157
  15. Shuteeva TV. The use of neipilept in treatment of asthenic syndrome. S.S. Korsakov Journal of Neurology and Psychiatry. 2018;118(2):81-84. (In Russ.). https://doi.org/10.17116/jnevro20181182181-84
  16. Corallo F, Scarfì C, Arcadi FA, et al. Role of functional pharmacological therapy in post-stroke depression: a narrative review. J Int Med Res. 2020;48(10):300060520950557. https://doi.org/10.1177/0300060520950557
  17. Arcadi FA, Corallo F, Torrisi M, et al. Role of citicoline and choline in the treatment of post-stroke depression: an exploratory study. J Int Med Res. 2021;49(11):3000605211055036. https://doi.org/10.1177/03000605211055036
  18. Shavlovskaya OA, Bokova IA. Recognan (citicoline) efficacy and safety in cognitive impairment correction of various nosological forms. S.S. Korsakov Journal of Neurology and Psychiatry. 2023;123(11):22-28. (In Russ). https://doi.org/10.17116/jnevro202312311122
  19. Amanzade A, Khakpai F, Zarrindast M-R. Synergistic antidepressant-like effect of citicoline and CB 1 agonist in male mice. Psychopharmacol (Berl). 2024;241(4):753-766.  https://doi.org/10.1007/s00213-023-06507-3
  20. Nejati S, Khakpai F, Zarrindast MR. Synergistic effect between citalopram and citicoline on anxiolytic effect in non-sensitized and morphine-sensitized mice: An isobologram analysis. Brain Res. 2020;1734:146701. https://doi.org/10.1016/j.brainres.2020.146701
  21. Nemkova SA, Semenov DV, Petrova EA, et al. Cognitive and emotional disorders in university students and teachers: the possibility of treatment with recognan (citicoline). S.S. Korsakov Journal of Neurology and Psychiatry. 2018;118(12):11-18. (In Russ.). https://doi.org/10.17116/jnevro201811812111
  22. Lipovka VP, Ivanov EA, Munika AA. Psychoemotional state of military personnel participating in the exercises. Actual Problems of Physical and Special Training of Law Enforcement Agencies. 2023;1:149-153. (In Russ).
  23. Shayan E, Maheri F, Aflaki F, et al. Synergistic effects of citicoline and silymarin nanomicelles in restraint stress-exposed mice. Behav Brain Res. 2024;464:114929. https://doi.org/10.1016/j.bbr.2024.114929
  24. Dean RL, Hurducas C, Hawton K, et al. Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder. Cochrane Database Syst Rev. 2021;9(9):CD011612. https://doi.org/10.1002/14651858.CD011612.pub3
  25. Khakpai F, Zarrindast MR. The effect of nicotine on antidepressant and anxiolytic responses induced by citalopram and citicoline in mice. Acta Neurobiol Exp (Wars). 2023;83(2):194-202.  https://doi.org/10.55782/ane-2023-017
  26. Khakpai F, Ramezanikhah M, Valizadegan F, Zarrindast M-R. Synergistic effect between imipramine and citicoline upon induction of analgesic and antidepressant effects in mice. Neurosci Let. 2021;760:136095. https://doi.org/10.1016/j.neulet.2021.136095
  27. Roohi-Azizi M, Arabzadeh S, Amidfar M, et al. Citicoline combination therapy for major depressive disorder: A randomized, double-blind, placebo-controlled trial. Clin Neuropharmacol. 2017;40(1):5.  https://doi.org/10.1097/WNF.0000000000000185
  28. Hart T, Benn EK, Bagiella E, et al. Early trajectory of psychiatric symptoms after traumatic brain injury: relationship to patient and injury characteristics. J Neurotrauma. 2014;31(7):610-617.  https://doi.org/10.1089/neu.2013.3041
  29. Zafonte RD, Bagiella E, Ansel BM, et al. Effect of citicoline on functional and cognitive status among patients with traumatic brain injury. JAMA. 2012;308(19):1993. https://doi.org/10.1001/jama.2012.13256
  30. Payamshad S, Khakpai F, Nasehi M, Zarrindast M-R. Effect of citicoline and transcranial direct current stimulation on depressive-like behaviors in mice & quot. Behav Brain Res. 2023;450:114495. https://doi.org/10.1016/j.bbr.2023.114495
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.